Equillium, Inc. (EQ) competitors & alternatives
Health Care · NASDAQ
Equillium, Inc. (EQ)'s top competitors and alternatives — its most similar public companies — include NEKTAR THERAPEUTICS (NKTR), FIRST TRACKS BIOTHERAPEUTICS INC (TRAX), ANAPTYSBIO INC (ANAB), NURIX THERAPEUTICS INC (NRIX), XENCOR INC (XNCR), ZURA BIO LTD CLASS A (ZURA), DIANTHUS THERAPEUTICS INC (DNTH), REZOLUTE INC (RZLT), DISC MEDICINE INC (IRON), CELLDEX THERAPEUTICS INC (CLDX), ORUKA THERAPEUTICS INC (ORKA) and AVALO THERAPEUTICS INC (AVTX). These are Equillium, Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top EQ competitors & alternatives
-
NEKTAR THERAPEUTICSNKTRHealth Care
A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
$69.32 (as of 2026-07-22) · market cap $2.4B
-
FIRST TRACKS BIOTHERAPEUTICS INCTRAXHealth Care
Clinical-stage antibody-focused biotech advancing immune-modulating therapies for autoimmune and inflammatory diseases including celiac disease, eosinophilic…
$38.17 (as of 2026-07-22) · market cap $1.3B
-
ANAPTYSBIO INCANABHealth Care
AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own…
$52.61 (as of 2026-07-22) · market cap $1.6B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
XENCOR INCXNCRHealth Care
Xencor is a clinical-stage biopharmaceutical company leveraging its proprietary XmAb antibody engineering platform to develop innovative multi-specific…
$19.51 (as of 2026-07-22) · market cap $1.4B
-
ZURA BIO LTD CLASS AZURAHealth Care
Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current…
$5.40 (as of 2026-07-22) · market cap $532M
-
DIANTHUS THERAPEUTICS INCDNTHHealth Care
Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing targeted complement-pathway inhibitors to treat severe autoimmune and…
$102.76 (as of 2026-07-22) · market cap $5.7B
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
DISC MEDICINE INCIRONHealth Care
Disc Medicine is a biopharmaceutical company developing targeted, mechanism-based therapies to treat serious hematologic diseases by modulating heme…
$74.32 (as of 2026-07-22) · market cap $2.8B
-
CELLDEX THERAPEUTICS INCCLDXHealth Care
A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin…
$34.77 (as of 2026-07-22) · market cap $2.7B
-
ORUKA THERAPEUTICS INCORKAHealth Care
Clinical-stage biopharmaceutical company developing novel monoclonal antibodies with extended half-life for inflammatory and immunology indications, led by…
$92.53 (as of 2026-07-22) · market cap $5.6B
-
AVALO THERAPEUTICS INCAVTXHealth Care
Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
$18.15 (as of 2026-07-22) · market cap $961M
Not quite? Describe exactly what you want →
Peers are Equillium, Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: Equillium, Inc. (EQ).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.